Salarius Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Decoy Therapeutics Inc. filed its Q2 2026 Form 10-Q, detailing ongoing operational losses, a significant cash burn, and a new risk of Nasdaq delisting.
Decoy Therapeutics reports Q1 2026 financial results, highlighting ongoing development of its IMP3ACT platform and a focus on extending cash runway.
Salarius Pharmaceuticals completed its merger with Decoy Therapeutics, shifting focus to AI-driven peptide conjugates, and raised $6.3 million in a public offering, extending its cash runway to Q1 2027.
Salarius Pharmaceuticals reported a reduced net loss in Q2 2025, driven by cost-cutting, as it navigates a critical merger with Decoy Therapeutics and ongoing Nasdaq listing compliance challenges.
Salarius Pharmaceuticals reports Q1 2025 results, highlighting ongoing losses, a proposed merger with Decoy Therapeutics, and challenges to maintain its Nasdaq listing.
Salarius Pharmaceuticals reports a net loss of $972,121 for Q3 2024 and expresses substantial doubt about its ability to continue as a going concern due to insufficient funding.
Salarius Pharmaceuticals is exploring strategic alternatives and implementing cost-saving measures due to financial constraints and has closed its Ewing sarcoma clinical trial, while a partial clinical hold impacts another trial.
Salarius Pharmaceuticals reported a net loss of $1.7 million for the first quarter of 2024, while implementing cost-saving measures and exploring strategic alternatives.